ProPhase Labs

ProPhase Labs PRPH Stock

$0.01   0.000000%
Add to favorites
Market Cap
$155.93K
LOW - HIGH [24H]
$0.01 - $0.01
VOLUME [24H]
$6.00
P/E Ratio
0
Earnings per share
-$0.87
ISIN
US74345W1080
Price   Prediction

ProPhase Labs Price Chart

Sorry, that's all we've gotfor now...

ProPhase Labs PRPH Financial and Trading Overview

ProPhase Labs stock price 0.0100 USD
Previous Close 0.01 USD
Open 0.0086 USD
Bid 0.0086 USD x 4000000
Ask 0.01 USD x 1275900
Day's Range 0.0086 - 0.0086 USD
52 Week Range 0.0086 - 4.2 USD
Volume 6 USD
Avg. Volume 313K USD
Market Cap 155.93K USD
Beta (5Y Monthly) 0.135
PE Ratio (TTM) N/A
EPS (TTM) -0.87 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date May 24, 2022
1y Target Est N/A

PRPH Valuation Measures

Enterprise Value 9.24M USD
Trailing P/E N/A
Forward P/E 0.020833334
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.040531583
Price/Book (mrq) N/A
Enterprise Value/Revenue 2.403
Enterprise Value/EBITDA -0.794

Trading Information

ProPhase Labs Stock Price History

Beta (5Y Monthly) 0.135
52-Week Change -99.73%
S&P500 52-Week Change 10.88%
52 Week High 4.2 USD
52 Week Low 0.0086 USD
50-Day Moving Average 0.02 USD
200-Day Moving Average 0.09 USD

PRPH Share Statistics

Avg. Volume (3 month) 313K USD
Avg. Daily Volume (10-Days) 599.54K USD
Shares Outstanding 15.59M
Float 15.31M
Short Ratio 0.11
% Held by Insiders 7.61%
% Held by Institutions 0.032%
Shares Short 289.01K
Short % of Float 3.38%
Short % of Shares Outstanding 3.21%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:10

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) June 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -261.62%
Gross Margin 16.76%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -19.55%
Return on Equity (ttm) -539.65%

Income Statement

Revenue (ttm) 3.85M USD
Revenue Per Share (ttm) 0.29 USD
Quarterly Revenue Growth (yoy) -18.89%
Gross Profit (ttm) 645K USD
EBITDA -11635000 USD
Net Income Avi to Common (ttm) -22463000 USD
Diluted EPS (ttm) -0.87
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 20K USD
Total Cash Per Share (mrq) 0.001 USD
Total Debt (mrq) 9.12M USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 0.048
Book Value Per Share (mrq) -0.222

Cash Flow Statement

Operating Cash Flow (ttm) -5542000 USD
Levered Free Cash Flow (ttm) 47.52M USD

Profile of ProPhase Labs

Country United States
State NY
City Uniondale
Address 626 RXR Plaz
ZIP 11556
Phone 516 989 0763
Website https://www.prophaselabs.com
Industry Diagnostics & Research
Sector(s) Healthcare
Full Time Employees 19

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA). It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Uniondale, New York.

Q&A For ProPhase Labs Stock

What is a current PRPH stock price?

ProPhase Labs PRPH stock price today per share is 0.0100 USD.

How to purchase ProPhase Labs stock?

You can buy PRPH shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for ProPhase Labs?

The stock symbol or ticker of ProPhase Labs is PRPH.

Which industry does the ProPhase Labs company belong to?

The ProPhase Labs industry is Diagnostics & Research.

How many shares does ProPhase Labs have in circulation?

The max supply of ProPhase Labs shares is 15.59M.

What is ProPhase Labs Price to Earnings Ratio (PE Ratio)?

ProPhase Labs PE Ratio is now.

What was ProPhase Labs earnings per share over the trailing 12 months (TTM)?

ProPhase Labs EPS is -0.87 USD over the trailing 12 months.

Which sector does the ProPhase Labs company belong to?

The ProPhase Labs sector is Healthcare.

ProPhase Labs PRPH included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.symbol }} {{ item.name }} {{ item.symbol }} {{ item.country.toUpperCase() }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
us US Tech Composite IXIC US 25955.34 USD —
-0.21
5.73B USD — 25866.15 USD — 26111.62 USD — — 5.73B USD —
us US Tech Composite Total Return XCMP US 32064.01 USD —
-0.21
— — 31953.83 USD — 32257.07 USD — — — —
us US Tech Capital Market Composite RCMP US 115.14 USD —
-1.35
— — 115.06 USD — 116.22 USD — — — —
$2.7T
Total marketcap
$52.98B
Total volume
BTC 59.51%   •   ETH 10.49%
Dominance
Select currency